Trends and practices for managing low-risk prostate cancer: a SEER-Medicare study.

Autor: Hoffman RM; Department of Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, USA. richard-m-hoffman@uiowa.edu.; Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA. richard-m-hoffman@uiowa.edu.; Department of Epidemiology, University of Iowa College of Public Health, Iowa City, IA, USA. richard-m-hoffman@uiowa.edu., Mott SL; Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.; Department of Epidemiology, University of Iowa College of Public Health, Iowa City, IA, USA., McDowell BD; Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.; Department of Epidemiology, University of Iowa College of Public Health, Iowa City, IA, USA., Anand ST; Department of Epidemiology, University of Iowa College of Public Health, Iowa City, IA, USA., Nepple KG; Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.; Department of Urology, University of Iowa Carver College of Medicine, Iowa City, IA, USA.
Jazyk: angličtina
Zdroj: Prostate cancer and prostatic diseases [Prostate Cancer Prostatic Dis] 2022 Mar; Vol. 25 (1), pp. 100-108. Date of Electronic Publication: 2021 Jun 09.
DOI: 10.1038/s41391-021-00393-6
Abstrakt: Background: Expectant management (EM) has been widely recommended for men with low-risk prostate cancers (PCa). We evaluated trends in EM and the sociodemographic and clinical factors associated with EM, initiating a National Comprehensive Cancer Network guideline-concordant active surveillance (AS) monitoring protocol, and switching from EM to active treatment (AT).
Methods: We used the SEER-Medicare database to identify men ages 66+ diagnosed with a low-risk PCa (PSA < 10 ng/mL, Gleason ≤ 6, stage ≤ T2a) in 2010-2013 with ≥1 year of follow-up. We used claims data to capture (1) PCa treatments, including surgical procedures, radiotherapy, and hormone therapy, and (2) AS monitoring procedures, including PSA tests and prostate biopsy. We defined EM as receiving no AT within 1 year of diagnosis. We used multivariable regression techniques to identify factors associated with EM, initiating AS monitoring, and switching to AT.
Results: During the study period, EM increased from 29.4% to 49.0%, p < 0.01. Age < 77, being married/partnered, non-Hispanic ethnicity, higher median ZIP code income, lower PSA levels, stage T1c, and more recent year of diagnosis were associated with EM. Nearly 39% of the EM cohort initiated AS monitoring; age <77, White race, being married/partnered, higher median ZIP code income, and lower PSA levels were associated with initiating AS. By three years after diagnosis, 21.3% of the EM cohort had switched to AT, usually after undergoing AS monitoring procedures.
Discussion: We found increasing uptake of EM over time, though over 50% still received AT. About 60% of EM patients did not initiate AS monitoring, even among those with life expectancy >10 years, implying that a substantial proportion was being managed by watchful waiting. AS monitoring was associated with switching to AT, suggesting that treatment decisions likely were based on cancer progression.
(© 2021. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.)
Databáze: MEDLINE
Externí odkaz: